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Background: Fabry disease is caused by a deficiency of α-galactosidase A (α-gal A), which leads to the systematic accumulation of 
glycosphingolipids, mainly globotriaosylceramide (Gb3). Cardiac variant of the disease (Cardiac Fabry disease) is found in 3% of male patients with 
left ventricular hypertrophy. The protein transduction domain from HIV Tat allows proteins to penetrate the cell membrane. Therefore we developed a 
novel recombinant lentiviral vector (LV) that engineer expression of α-gal A-Tat fusion protein (LV/α-gal A-Tat). 
Methods: HeLa cells were transduced with LV/α-gal A or LV/α-gal A-Tat. Enzyme activity in the supernatant of transduced cells was analyzed and 
enzyme uptake assays was performed. Next we injected PBS or recombinant LVs (LV/α-gal A-Tat, LV/α-gal A or LV/enGFP) into temporal vein of 
neonatal α-gal A-deficient mice with two different LV dose (high or low dose). Plasma enzyme activity was measured every 4 weeks. We evaluated 
organ enzyme activity and GB3 levels at sacrifice. 
Results: We detected higher α-gal A activity in the supernatant of transduced cells compared with that of non-transduced cells. Enzyme uptake 
assays confirmed that the α-gal A-Tat fusion protein allowed for mannose-6-phosphate (M6P) receptor-independent uptake. Plasma α-gal 
A activities increased significantly in both the LV/α-gal A and LV/α-gal A-Tat-treated group compared to PBS-injected group in the high dose 
experiment, but not in low dose one. This increase of α-gal A activity was stable and consistent until the termination of the experiment. Analysis 
of tissues at 26 weeks demonstrated similar α-gal A enzyme activities but enhanced Gb3 reduction in the heart and kidney of the LV/α-gal A-Tat 
treated group compared to LV/α-gal A treated group in the high dose experiment. Moreover, even though we used only one-quarter of the LV stock 
for injections in low dose experiment, there were still statistically significant differences in Gb3 levels in heart between both treated groups. 
Conclusion: We demonstrated greater Gb3 reduction in the heart using α-gal A-Tat fusion protein. This strategy might advance not only gene 
therapy but also ERT for Fabry disease, especially cardiac Fabry disease.
